Ingenuity Systems and CLC bio joined forces to increase synergy between their software solutions. They hope to provide researchers performing both array and next-generation sequencing with the ability to more easily exchange data between CLC bio’s genomic analysis products and Ingenuity’s pathway analysis software (IPA). The first milestone of the partnership is focused upon streamlined workflows between CLC bio’s CLC Genomics Server, CLC Genomics Workbench, and Ingenuity’s IPA.
The CLC Genomics Workbench facilitates the analysis and visualization of next-generation sequencing data and helps streamline users’ workflow. The CLC Genomics Server is a high-throughput sequencing-focused three-tier solution, offering bioinformatics computing on a server-architecture located centrally in the client’s organization. CLC bio says that these products offer various solutions for building and managing a modern and efficient enterprise-wide bioinformatics platform in organizations of any size.
Ingenuity’s IPA software aids in the modeling, analysis, and understanding of complex biological and chemical systems. It integrates data from a variety of experimental platforms and provides insight into the molecular and chemical interactions, cellular phenotypes, and disease processes of a system.
IPA leverages the Ingenuity Knowledge Base, a repository of biological interactions and functional annotations created from millions of individually modeled relationships between proteins, genes, complexes, cells, tissues, drugs, and diseases.
“The costs of sequencing full genomes are now at a price level where we see a lot of industries and research areas moving into high-throughput sequencing in order to benefit from the added scientific value these new technologies can provide,” says director of consulting solutions at CLC bio, Jannick D. Bendtsen, Ph.D.
“The interoperability of Ingenuity’s IPA with CLC Genomics Server and CLC Genomics Workbench is a solution that will provide an efficient workflow experience for scientists working with large next-generation sequencing datasets, directly from high-performance analyses to biomarker discovery and research diagnostic development.”